Preview

Bone and soft tissue sarcomas, tumors of the skin

Advanced search

Clinical efficacy and safety of isolated limb perfusion with hyperthermia. Comparative study in patients with limb melanoma

Abstract

Aim. Аssessment of the effectiveness of patients with melanoma limbs treatment using the isolated perfusion chemotherapy in the conditions of hyperthermia.
Methods. It performed the analysis of 41 patients with lower extremity of disseminated melanoma treatment results. Patients were divided into 2 groups: main group – 24 patients received treatment with an isolated regional perfusion (prI), melphalan (10 mg/ l volume of the lower limbs); comparison group – 17 patients are treated with conventional methods with the implementation of mutilation were used. When the prI used the original methodology for monitoring chemotherapy income levels in the systemic circulation.
Results. It was found that the application of the procedure of isolated regional perfusion for locally disseminated melanoma of the skin contributes to significant increase in survival of patients: the overall two-year survival rate was up to 91,7% compared to 53,8% with standard treatment. local toxicity associated with carrying out the isolated limb perfusion was regional, in most cases did not exceed grade I and II on the extent Wieberdink scale. no cases of systemic toxicity of grade I–II CTC scale were observed, confirming the satisfactory safety of this method in the treatment of cancer.
Conclusion. method of isolated regional limb perfusion is clinically effective and safe in the treatment of locally disseminated melanoma of the skinlimbs, its use can reduce the incidence of recurrence of the disease and avoid performing the amputation surgery.

About the Authors

T. K. Kharatishvili
N.N. Blokhin Russian Cancer Research Center Ministry of Health of the Russian Federation
Russian Federation

Moscow



N. S. Petrochenko
N.N. Blokhin Russian Cancer Research Center Ministry of Health of the Russian Federation
Russian Federation

Moscow



Y. V. Buydenok
N.N. Blokhin Russian Cancer Research Center Ministry of Health of the Russian Federation
Russian Federation

Moscow



M. D. Aliev
N.N. Blokhin Russian Cancer Research Center Ministry of Health of the Russian Federation
Russian Federation

Moscow



References

1. Alexander H.R., Fraker D.L., Bartlett D.L. et al. Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoin isolated limb perfusion using modern treatment parameters. J. Clin. Oncol. 2010, v. 28, p. 114-118.

2. Coventry B.J., Ashdown M.L. Complete clinical responses to cancer therapy caused by multiple divergent approaches: a repeating theme lost in translation. Cancer Manag. Res. 2012, v. 4, p. 137-149.

3. Dong X.D., Tyler D., Jonson J.L. et al. Analysis of prognosis and disease progression alter local recurrence of melanoma. Cancer. 2000, v. 88, p. 1063-1071.

4. Vrouenraets B.C., Hart G.A., Eggermont A.M. et al. Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J. Am. Coll. Surg. 1999, v. 188, p. 522-530.

5. Rossi C.R., Foletto M., Mocellin S. et al. Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and melphalan for bulky in-transit melanoma metastases. Ann. Surg. Oncol. 2004, v. 11, p. 173-177.

6. Moreno-Ramirez D., de la Cruz-Merino L., Ferrandiz L. et al. Study an treatment of locally advanced melanoma. Actas. Dermosifiliogr. 2009, v. 100, p. 767-779.

7. Thompson J.F., Hersey P., Wachter E. Chemoablation of metastatic melanoma using intralesional rose bengal. Melanoma Res. 2008, v. 18, p. 405-411.

8. Noorda E.M., van Kreij R.H., Vrouenraets B.C. et al. The health-related quality of life of long-term survivors of melanoma treated with isolated limb perfusion. Eur. J. Surg. Oncol. 2007, v. 33, p. 776-782.

9. Olofsson Bagge R., Mattsson J., Hafstrom L. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities long-term follow-up of a randomized trial. Int. J. Hyperthermia. 2014, v. 30 (5), p. 295-298.

10. Hoekstra H.J., Veerman K., van Ginkel R.J. Isolated limb perfusion for in-transit melanoma metastases: melphalan or TNF-melphalan perfusion? J. Surg. Oncol. 2014, v. 109 (4), p. 338-347.

11. Giles M.H., Coventry B.J. Isolated limb infusion chemotherapy for melanoma: an overview of early experience at the Adelaide Melanoma Unit. Cancer Manag. Res. 2013, v. 20 (5), p. 243-249.

12. Kroon H.M., Moncrieff M., Kam P.C., Thompson J.F. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann. Surg. Oncol. 2008, v. 15, p. 3003-3013.

13. Coventry B.J., Kroon H.M., Giles M.H. et al. Australian multi-center experience outside of the Sydney Melanoma Unit of isolated limb infusion chemotherapy for melanoma. J. Surg. Oncol. 2014, v. 109 (8), p. 780-785.


Review

For citations:


Kharatishvili T.K., Petrochenko N.S., Buydenok Y.V., Aliev M.D. Clinical efficacy and safety of isolated limb perfusion with hyperthermia. Comparative study in patients with limb melanoma. Bone and soft tissue sarcomas, tumors of the skin. 2016;(3):34-40. (In Russ.)

Views: 95


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2219-4614 (Print)
ISSN 2782-3687 (Online)